<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26789">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757989</url>
  </required_header>
  <id_info>
    <org_study_id>MDS-ALLO-RISK</org_study_id>
    <secondary_id>2015-A00292-47</secondary_id>
    <nct_id>NCT02757989</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk</brief_title>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM &amp; SFGM-TC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of survival in patients with or without a matched donor at 36 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
      received an allogeneic hematopoietic stem cell transplantation.

      Patients without a matched donor received the best available treatment. All patients will be
      followed at least 36 months or until the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>comparison of overall survival in patients with or without a matched donor (8/8 unrelated donor or matched sibling) at 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>comparison of quality of life in patients with or without a matched donor, quality of life assessed by questionnaire (EORTC version 3) at inclusion, 12, 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete response at 36 month</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for cumulative incidence of complete response at 36 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with transformation in AML at 36 month</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for cumulative incidence of transformation in AML at 36 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with iron overload</measure>
    <time_frame>16 months</time_frame>
    <description>proportion of patients with iron overload (Serum Ferritin (SF)&gt;1000 ng/mL or Red Blood Cells transfusion&gt;20) at time of inclusion and at 16 month after inclusion for non-transplanted patients and 12 months post-transplant for transplanted patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of innovative iron markers including Non-transferrin binding iron (NTBI), labile plasmatic Iron (LPI) and Hepcidine</measure>
    <time_frame>3 and 16 months</time_frame>
    <description>evolution of innovative iron markers including Non-transferrin binding iron (NTBI), labile plasmatic Iron (LPI) and Hepcidine measured at time of inclusion, at 3 month and 16 month post-inclusion for all patients; In transplanted patients these markers will be measured just before conditioning regimen (J-5), Just before the transplantation (J0), at D7, 30, 100 and 12 month after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficiency of chelation</measure>
    <time_frame>3 and 16 months</time_frame>
    <description>the effect of chelation will be assessed at 3 month after inclusion for all patient and post transplant by measuring Serum ferritin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with adverse events grade III and IV as assessed by CTCAE v4.0</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for number of Grade III and IV toxicities (hematological and non-hematological) recorded according to NCI CTCAE criteria versions 4.0 during the 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Patients with donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without donor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without a matched donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>transplantation</intervention_name>
    <description>allogeneic hematopoietic stem cell transplantation in patients with donor</description>
    <arm_group_label>Patients with donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed consent

          2. All patients should have the following disease criteria together

               -  MDS classified according to classical IPSS as intermediate 1 or low

               -  MDS classified according to revised IPSS at least intermediate

               -  Patients who failed to an approved treatment which can be EPO, lenalidomide or
                  Vidaza® or who are not eligible for such a treatment or who have
                  thrombocytopenia &lt; 20 G/L requiring transfusion or neutropenia &lt; 0.5 G/L
                  associated with severe infection (defined as requiring hospitalization)

          3. Age ≥ 45 and &lt; 70 years

          4. Patient for whom a transplantation from a matched donor, (8/8 (HLA A, B, C, DRB1)
             identical at molecular level)unrelated donor or matched sibling), is considered
             irrespective of donor availability

          5. Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale (At
             time of screening)

          6. Negative pregnancy and adequate contraception (including in male patients wishing to
             father), if relevant.

          7. Wash-out of at least 30 days since a previous treatment with Vidaza, Lenalidomide,
             EPO or any other treatment inducing cytopenias.

        Exclusion Criteria:

          1. MDS classified according to classical IPSS as intermediate 2 or High risk

          2. Transformation in Acute myeloid Leukemia (AML)

          3. Severe active infection or any other uncontrolled severe condition.

          4. Organ dysfunctions including the following

               -  Hepatic : total bilirubin &gt; 2 times upper limit of normal (ULN) (except moderate
                  unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert
                  syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) &gt; 3xULN

               -  Symptomatic respiratory chronic failure

               -  Symptomatic cardiac failure

               -  Renal clearance &lt; 60ml/min

          5. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or
             other tumors if not active during the last 3 years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Robin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Robin, MD</last_name>
    <phone>+33 1 42 49 96 60</phone>
    <email>marie.robin@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Sébert, MD</last_name>
    <phone>+33 1 71 20 70 23</phone>
    <email>marie.sebert@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bérengère Gruson, MD</last_name>
      <phone>+33 3 22 45 59 14</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bérengère Gruson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD, PHD</last_name>
      <phone>+33 3 81 66 83 51</phone>
      <email>edeconinck@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Berceanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Braun, MD</last_name>
      <phone>+33 1 48 95 70 57</phone>
      <email>thorsten.braun@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Haut Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Vigouroux, MD</last_name>
      <phone>+33 5 57 65 67 27</phone>
      <email>stephane.vigouroux@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Vigouroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Dimicoli-Salazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Cheze, MD</last_name>
      <phone>+33 2 31 27 23 60</phone>
      <email>cheze-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Cheze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oumedaly Reman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Olivier Bay, MD</last_name>
      <phone>+33 4 73 75 00 65</phone>
      <email>jobay@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Olivier Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit De Renzis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Yves Cahn, MD, PHD</last_name>
      <phone>+33 4 76 76 56 63</phone>
      <email>jycahn@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves Cahn, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Park, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rose, MD, PHD</last_name>
      <phone>+33 3 20 87 45 32</phone>
      <email>rose.christian@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christian Rose, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauricette Michallet, MD, PHD</last_name>
      <phone>+33 4 78 86 22 05</phone>
      <email>mauricette.michallet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Mauricette Michallet, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wattel, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Fegueux, MD</last_name>
      <phone>+33 4 67 33 83 63</phone>
      <email>n-fegueux@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Fegueux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, MD</last_name>
      <phone>+33 2 40 08 33 33</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Peterlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Robin, MD</last_name>
      <phone>+33 1 42 49 96 60</phone>
      <email>marie.robin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Robin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Sébert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Hermine, MD, PHD</last_name>
      <phone>+33 1 44 49 53 68</phone>
      <email>olivier.hermine@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Hermine, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Suarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Sanhes, MD</last_name>
      <phone>+33 4 68 61 64 48</phone>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Sanhes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia Stamatoullas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aspasia Stamatoullas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Huynh, MD</last_name>
      <phone>+33 5 31 15 61 91</phone>
      <email>huynh.anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odile Beyne-Rauzy, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Recher, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan, MD, PHD</last_name>
      <phone>+33 2 47 25 87 78</phone>
      <email>e.gyan@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Gyan, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>May 2, 2016</lastchanged_date>
  <firstreceived_date>March 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low risk MDS</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
